Dear visitor

It looks like you want to view this
website in a different language.

Please click here to view this website in English.
icon

Short Term Technical Advisor

KNCV Tuberculosis Foundation is looking for a;

Short Term Technical Advisor for reviewing the KNCV Tuberculosis Foundation and CEPHEID HBDC Collaboration Project ‘GeneXpert MTB/RIF technology 2015-2016’ (2nd phase) in Nigeria

Terms of Reference

About KNCV
KNCV Tuberculosis Foundation is an international non-profit organization dedicated to the fight against tuberculosis (TB), still the second most deadly infectious disease in the world.
KNCV is an international center of expertise for TB control that promotes effective, efficient, innovative and sustainable tuberculosis control strategies in a national and international context. We are an organization of passionate TB professionals, including doctors, researchers, training experts, nurses and epidemiologists. We aim to stop the spread of the worldwide epidemic of TB and to prevent the further spread of drug-resistant TB.

Over the past century we have built up a wealth of knowledge and expertise, initially by successfully controlling TB in the Netherlands. Since the 1970s, we have also shared our knowledge and expertise with the rest of the world. We operate from a central office in The Hague in the Netherlands, a regional office in Central Asia and country offices worldwide. KNCV raises funds from private, institutional, corporate, and government donors

Background to the Project
The GeneXpert MTB/RIF test from Cepheid HBDC, endorsed by the World Health Organization (WHO) for roll-out in 2010, has tremendous potential for improving tuberculosis (TB) diagnostic capacity and, as such, TB control in high-burden countries. The use of the GeneXpert MTB/RIF test is increasing exponentially at a global level. However, resource-constrained countries are faced with some operational difficulties and sub-optimal performance issues. These include, amongst other challenges, the following domains: (i) strategic planning of where to place the GeneXpert MTB/RIF instruments; (ii) how to use them in a standardized fashion with a clear diagnostic algorithm; (iii) procurement and supply chain management of GeneXpert MTB/RIF supplies; (iv) required laboratory infrastructure (e.g., uninterruptable power supply, power surge protectors, electricity, air-conditioning, security); (v) training; (vi) routine supervision of laboratory and clinical staff; (vii) monitoring and evaluation of the quality of services (including linkages of the GeneXpert MTB/RIF test result with treatment and treatment outcome);(viii) installation and maintenance; (ix) troubleshooting.

KNCV supports implementation and scaling-up of GeneXpert MTB/RIF in a large number of countries as well as within regional and global fora. To date, for example, we have conducted the following endeavors related to GeneXpert MTB/RIF: (i) directly supported roll-out in various countries; (ii) developed global technical implementation materials for strategic integration of GeneXpert MTB/RIF including a strategic planning handbook, pre-site selection checklists, standardized recording and reporting forms; (iii) trained consultants from the TB CARE I coalition to support the roll-out of GeneXpert MTB/RIF; (iv) supported the development of standardized training modules for GeneXpert MTB/RIF roll-out with WHO and FIND; (v) conducted cost-effectiveness studies on GeneXpert MTB/RIF technology. Notwithstanding, over the last year, we have successfully piloted, with our Cepheid HBDC and KNCV partnership, GeneXpert service provision in Nigeria and Vietnam.

Purpose of the Assignment
To address the above general challenges, KNCV provides country and regional technical service packages of activities to maximize the diagnostic benefit of Xpert including capacity building within the National TB program, National AIDS program and the national laboratory networks.

Besides our internal expertise and tools, KNCV also uses reputable tools that are globally available for GeneXpert MTB/RIF implementation through the Global Laboratory Initiative (GLI), the World Health Organization, from Cepheid HBDC (the manufacturer), TB CARE I, Challenge TB as well as any future technical collaboration that provides technically sound and free tools.

The consultant will:

  1. Evaluate if the project is completing the activities that it is designed to conduct (since its inception) and assess if the objectives will be met;
  2. Assess if the project has demonstrated any outcome that would justify the assumption that it supports the Nigeria TB strategy as well as the KNCV strategy (e.g., to increase case-detection and reduce the burden of TB)
  3. Assess quantitative and qualitative aspects for the projects outputs
  4. Identify issues that hinder the project from performing its activities effectively
  5. Determine what is the perception of key stakeholders of the project
  6. Evaluate if there any risk to KNCV due to this project and if so how might they be further mitigated
  7. Assess if there is a mechanism to make this initiative more sustainable for KNCV to pull-out and if so what might be the time line.
  8. Consider with expansion plan of Xpert in Nigeria how the business model for this project (should it be extended) should be revised
  9. Establish performance indicators for future monitoring of the project

Deliverables
Evaluation report, addressing the specific objectives as stated above.

Methodology:

  • Desk review of contractual agreements, SOPs, protocols and existing reports as well as Access database.
  • Look at database of activities conducted since inception of the project as well as paper records
  • Interview stakeholders on the qualitative aspects of the project (perceived benefits, perceived gaps etc.)
  • In-depth interview with the country team coordinator
  • Interviews with all implementing partners (NTP, NACA, CIHP, CTB, DOD, IHVN, CHAI, FHI) during a Country GeneXpert Advisory Team (CGAT) meeting

Reporting
The TA individual or organization operates under the supervision of the KNCV Country Director for Nigeria when in country and reports directly to the technical lead of the Cepheid project at KNCV HQ.

Timeframe & locations
The activity should take place in in Nigeria in July 2016. Exact dates are open for negotiation.

  • Preparation:
    2 days preparation with review of available background documents
  • On site activities
    5 days for the interviews of stakeholders and data collection in-country
  • Reporting
    3 days reporting
  • Travel
    2 travel days to review location and back to station

Requirements
• Proven track record of evaluating projects as an external reviewer, preferably in Nigeria/Africa;
• Knowledge of TB/ public health programs would be preferred;
• Knowledge of GeneXpert would be a plus but not a requirement.

Conditions
• A consultancy contract for the period of the assignment;
• An international environment where initiative is appreciated;
• A fee that is competitive for the scope of the assignment;

Application and information
Your application (curriculum vitae, proof of prior experience and proficiency in the stated assignment and proposed work plan imbedded in your cover letter) should be sent by July 12 to:
Dianne van Oosterhout (dianne.vanoosterhout@kncvtbc.org).
For more information please contact us: email jerod.scholten@kncvtbc.org; dianne.vanoosterhout@kncvtbc.org. For further information on KNCV Tuberculosis Foundation, please see www.kncvtbc.org.